MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$10,413,205
Interest income
$125,644
Total operating costs
$10,538,849
General and
administrative expenses
$8,103,280
Research and development
expenses
$2,435,569
Back
Back
Income Statement
source: myfinsight.com
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)